"Febuxostat" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.
| Descriptor ID |
D000069465
|
| MeSH Number(s) |
D02.886.675.274 D03.383.129.708.274
|
| Concept/Terms |
TEI 6720- TEI 6720
- 6720, TEI
- TEI-6720
- TEI6720
|
Below are MeSH descriptors whose meaning is more general than "Febuxostat".
Below are MeSH descriptors whose meaning is more specific than "Febuxostat".
This graph shows the total number of publications written about "Febuxostat" by people in this website by year, and whether "Febuxostat" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 2 | 5 |
| 2019 | 1 | 2 | 3 |
| 2020 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Febuxostat" by people in Profiles.
-
Gout Pharmacotherapy in Cardiovascular Diseases: A Review of Utility and Outcomes. Am J Cardiovasc Drugs. 2021 Sep; 21(5):499-512.
-
Febuxostat therapy in outpatients with suspected COVID-19: A clinical trial. Int J Clin Pract. 2020 Nov; 74(11):e13600.
-
The emerging role of xanthine oxidase inhibition for suppression of breast cancer cell migration and metastasis associated with hypercholesterolemia. FASEB J. 2019 06; 33(6):7301-7314.
-
Fresh Perspectives on the CARES Trial and the Use of Febuxostat in an Asian Population: Comment on the Article by Choi et al. Arthritis Rheumatol. 2019 03; 71(3):479-481.
-
Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update. Cardiol J. 2019; 26(1):99-101.
-
Gout - An update of aetiology, genetics, co-morbidities and management. Maturitas. 2018 Dec; 118:67-73.
-
Cardiovascular Safety of Febuxostat. N Engl J Med. 2018 10 18; 379(16):1583.
-
Febuxostat for the treatment of hyperuricaemia in gout. Expert Opin Pharmacother. 2018 Aug; 19(11):1289-1299.
-
Chronic Disease Approaches Needed to Curb Gout's Growing Burden. JAMA. 2018 Apr 03; 319(13):1307-1309.
-
Efficacy of febuxostat in hyperuricemic patients with mild-to-moderate chronic kidney disease: a meta-analysis of randomized clinical trials: A PRISMA-compliant article. Medicine (Baltimore). 2018 Mar; 97(13):e0161.